当前位置:首页 - 行情中心 - 昭衍新药(603127) - 财务分析 - 现金流量表

昭衍新药

(603127)

  

流通市值:261.71亿  总市值:311.11亿
流通股本:6.30亿   总股本:7.49亿

现金流量表

报告期2025-06-302025-03-312024-12-312024-09-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金835,220,095.37393,009,966.081,741,329,969.611,302,922,496.39
  收到的税费返还3,521,200.65806,423.224,566,588.323,633,470.76
  收到其他与经营活动有关的现金37,237,275.8435,988,568.2265,490,488.2261,135,423.58
  经营活动现金流入小计875,978,571.86429,804,957.521,811,387,046.151,367,691,390.73
  购买商品、接受劳务支付的现金255,061,869.13109,851,243.37564,165,327.08450,455,951.77
  支付给职工以及为职工支付的现金362,670,351.19202,650,410.26676,070,205.23531,824,473.43
  支付的各项税费44,636,272.5826,290,323.55118,651,811.76108,325,574.33
  支付其他与经营活动有关的现金50,837,084.1325,863,779.18113,570,983.6884,759,681.86
  经营活动现金流出小计713,205,577.03364,655,756.361,472,458,327.751,175,365,681.39
  经营活动产生的现金流量净额162,772,994.8365,149,201.16338,928,718.4192,325,709.34
二、投资活动产生的现金流量:
  收回投资收到的现金1,017,911,291.67611,998,0003,160,885,508.222,307,885,508.22
  取得投资收益收到的现金20,527,967.295,612,767.24194,848,031.42190,456,675.35
  处置固定资产、无形资产和其他长期资产收回的现金净额36,965.242,945.24568,427.13555,931.64
  收到的其他与投资活动有关的现金--9,200,0009,200,000
  投资活动现金流入小计1,038,476,224.2617,613,712.483,365,501,966.772,508,098,115.21
  购建固定资产、无形资产和其他长期资产支付的现金89,303,769.2446,814,440.04269,391,239.71188,019,727.66
  投资支付的现金1,384,184,774.91904,759,050.915,059,134,712.63,270,129,154.26
  投资活动现金流出小计1,473,488,544.15951,573,490.955,328,525,952.313,458,148,881.92
  投资活动产生的现金流量净额-435,012,319.95-333,959,778.47-1,963,023,985.54-950,050,766.71
三、筹资活动产生的现金流量:
  分配股利、利润或偿付利息支付的现金--119,633,363.2119,633,363.2
  支付其他与筹资活动有关的现金28,180,254.5718,665,128.1145,994,123.77129,194,728.77
  筹资活动现金流出小计28,180,254.5718,665,128.1265,627,486.97248,828,091.97
  筹资活动产生的现金流量净额-28,180,254.57-18,665,128.1-265,627,486.97-248,828,091.97
四、汇率变动对现金及现金等价物的影响-2,551,375.3-1,154,223.861,278,854.73-6,969,366.76
五、现金及现金等价物净增加额-302,970,954.99-288,629,929.27-1,888,443,899.38-1,013,522,516.1
  加:期初现金及现金等价物余额965,203,128.59965,201,085.722,853,647,027.972,853,647,027.97
  期末现金及现金等价物余额662,232,173.6676,571,156.45965,203,128.591,840,124,511.87
补充资料:
  净利润60,932,376.38-69,755,063.9-
  资产减值准备66,010,456.08-66,540,016.67-
  固定资产和投资性房地产折旧45,228,713.36-86,371,570.67-
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧45,228,713.36-86,371,570.67-
  无形资产摊销8,041,663.14-15,255,792.01-
  长期待摊费用摊销10,656,937.26-17,890,874.87-
  递延收益摊销8,924,489.34--6,566,775.31-
  处置固定资产、无形资产和其他长期资产的损失44,025.87-48,130.43-
  固定资产报废损失-152,132.42-161,723.95-
  公允价值变动损失-107,019,073.28-127,048,597.78-
  财务费用-30,344,182.68--56,311,351.88-
  投资损失-13,135,262.03--36,011,545.69-
  递延所得税1,267,989.53--40,245,864.96-
  其中:递延所得税资产减少3,917,588.08--5,105,168.52-
    递延所得税负债增加-2,649,598.55--35,140,696.44-
  存货的减少-24,389,766.63-384,195,565.07-
  经营性应收项目的减少84,804,281.28--5,146,312.12-
  经营性应付项目的增加43,202,349.46--331,889,262.21-
  现金的期末余额662,232,173.6-965,203,128.59-
  减:现金的期初余额965,203,128.59-2,853,647,027.97-
  现金及现金等价物的净增加额-302,970,954.99--1,888,443,899.38-
公告日期2025-08-272025-04-292025-03-292024-10-31
审计意见(境内)标准无保留意见
TOP↑